Jeremy P. Springhorn Sells 2,112 Shares of uniQure N.V. (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Jeremy P. Springhorn sold 2,112 shares of the company’s stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the sale, the director now directly owns 37,694 shares in the company, valued at $544,678.30. This trade represents a 5.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

uniQure Stock Performance

uniQure stock opened at $14.33 on Thursday. The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99. The firm has a market capitalization of $785.00 million, a P/E ratio of -3.26 and a beta of 0.08. uniQure N.V. has a 1-year low of $3.73 and a 1-year high of $19.18. The company’s 50-day moving average is $14.48 and its 200 day moving average is $13.99.

uniQure (NASDAQ:QURE) last released its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. The firm had revenue of $1.57 million for the quarter, compared to analysts’ expectations of $5.93 million. Research analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on QURE shares. Chardan Capital restated a “buy” rating and issued a $38.00 price target on shares of uniQure in a research report on Friday, May 30th. Guggenheim restated a “buy” rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. Wells Fargo & Company lowered their price target on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Cantor Fitzgerald upgraded uniQure to a “strong-buy” rating in a research report on Monday, May 19th. Finally, HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of uniQure in a research report on Thursday, May 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $37.82.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently bought and sold shares of the business. Woodline Partners LP lifted its position in shares of uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares during the last quarter. 683 Capital Management LLC lifted its holdings in uniQure by 1.6% during the 1st quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company’s stock valued at $16,430,000 after buying an additional 25,000 shares in the last quarter. Vestal Point Capital LP lifted its holdings in uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after buying an additional 1,767,572 shares in the last quarter. Birchview Capital LP boosted its position in uniQure by 343.5% in the 1st quarter. Birchview Capital LP now owns 88,697 shares of the biotechnology company’s stock valued at $940,000 after buying an additional 68,697 shares during the period. Finally, Nantahala Capital Management LLC grew its stake in uniQure by 3.8% in the 1st quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock worth $29,213,000 after acquiring an additional 101,598 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.